We came across a bullish thesis on ARS Pharmaceuticals, Inc. on Value Degen’s Substack’s Substack by Unemployed Value Degen. In this article, we will summarize the bulls’ thesis on SPRY. ARS Pharmaceuticals, Inc.'s share was trading at $10.15 as of September 11th.
ARS Pharmaceuticals (ARS) is positioned in the epinephrine delivery market with its nasal spray, Neffy, supported by a portfolio of patents covering composition, formulation, dosage, delivery devices, and absorption-enhancing companion drugs, with protections extending to 2039. These patents are currently under legal...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.